New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort

  title={New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort},
  author={M{\'a}ria Papp and Istv{\'a}n T Altorjay and Nir Dotan and K{\'a}roly Palatka and Ildiko Foldi and Judit Tumpek and Sándor Sipka and Mikl{\'o}s L Udvardy and Tam{\'a}s Dinya and L{\'a}szl{\'o} Lakatos and {\'A}gota Kov{\'a}cs and Tam{\'a}s Moln{\'a}r and Zsolt Tulassay and P{\'a}l Miheller and Gary L. Norman and Tam{\'a}s Szamosi and J{\'a}nos Papp and Peter Laszlo Lakatos},
  journal={The American Journal of Gastroenterology},
BACKGROUND:Antibodies to Saccharomyces cerevisiae (S. cerevisiae) (ASCA) and porin protein-C of Escherichia coli (anti-OmpC) are associated with disease phenotype and may be of diagnostic importance in inflammatory bowel diseases (IBD). Our aim was to determine whether a panel of new antibodies against bacterial proteins and carbohydrates could help differentiate among the various forms of IBD, and whether they were associated with particular clinical manifestations in a Hungarian cohort of IBD… 
Pancreatic Autoantibodies Are Associated with Reactivity to Microbial Antibodies, Penetrating Disease Behavior, Perianal Disease, and Extraintestinal Manifestations, But Not with NOD2/CARD15 or TLR4 Genotype in a Hungarian IBD Cohort
PAB autoantibodies in combination with ASCA or anti‐glycan antibodies increase the sensitivity for detecting Crohn's disease, especially isolated colonic CD.
New serological markers in pediatric patients with inflammatory bowel disease.
Identification of patients at an increased risk of rapid disease progression is of great interest, as the application of early and more aggressive pharmaceutical intervention could have the potential to alter the natural history of IBD, and reduce complications and hospitalizations.
Serological markers of inflammatory bowel disease
  • A. Kuna
  • Biology, Medicine
    Biochemia medica
  • 2013
Current evidence suggests that serologic panels of multiple antibodies are useful in differential diagnosis of CD versus UC and can be a valuable aid in stratifying patients according to disease phenotype and risk of complications.
Serological Markers in Inflammatory Bowel Disease
Serological markers linked to CD, such as anti-Saccaromyces cerevisiae, anti-Pseudomonas-associated sequence I2, outer membrane porin C of Escherichia coli antibodies and antibodies against the bacterial flagellin CBir1, as well as markers linked as perinuclear anti-neutrophil cytoplasmic antibodies, p-ANCA, have been extensively investigated for diagnosis and disease stratification.
Serological markers predict inflammatory bowel disease years before the diagnosis
A panel of serological markers is able to predict development of CD and UC in individuals from a low-risk population and the predictive value of the combination of markers increased when time to diagnosis of CD or UC decreased.
Serological markers in inflammatory bowel disease: a review of their clinical utility.
Assessing both ASCA and pANCA allows a better differentiation of Crohn's disease from ulcerative colitis than by using the individual tests alone, and these serological markers may act as prognostic indicators of the severity and behavior of IBD.
Significance of anti-Saccharomyces cerevisiae IgA and IgG antibodies in inflammatory bowel disease (ulcerative colitis and Crohn's disease) of Iraqi patients
The frequency distribution of positive cases for gASC antibodies showed a significant variation between IBD patients (UC and CD) and controls, and such varia on was related to an increased frequency of posi ve cases in UC (24.1%) and CD (76.0%) and controls compared to controls (0.0%).
pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis—A Longitudinal Report from the IBD Porto Group of ESPGHAN
Serology may have some role in predicting disease course and outcomes in colonic IBD, but its routine use needs to be supported by more studies andSerology cannot routinely be recommended for differentiating between IBDU versus CC or UC as a sole diagnostic criterion given its low diagnostic utility.
Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review
There is currently insufficient evidence to recommend the use of antibody testing to predict responses to treatment or surgery in patients with IBD, but the combined presence and magnitude of a large panel of antibodies appear to be of value in predicting disease progression.
Serologic Markers: Impact on Early Diagnosis and Disease Stratification in Inflammatory Bowel Disease
  • R. Arai
  • Medicine, Biology
    Postgraduate medicine
  • 2010
Serologic panels of multiple IBD biomarkers can be used to identify the relative risk of progression to complicated disease behaviors, and that this information may ultimately impact therapeutic decisions.


Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients
Serological markers were useful in the differentiation between CD and UC in an Eastern European IBD cohort, and Reactivity to microbial components was associated with disease phenotype and NOD2/CARD15 genotype, further supporting the role of altered microbial sensing in the pathogenesis of CD.
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
The number and magnitude of immune responses to different microbial antigens were shown to be associated with the severity of the disease and the predictive role of serological markers are necessary.
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease
Specificity of serological markers for IBD is high, but low sensitivity makes them less useful as diagnostic tests and the usefulness of these markers in indeterminate colitis needs to be studied prospectively.
Utility of serological markers in inflammatory bowel diseases: gadget or magic?
An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease and are at higher risk for surgery than those without, or with low titers of antibodies.
Antibodies to Saccharomyces cerevisiae in Crohn's disease: Higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease
Higher ASCA titers were associated with higher probabilities of ileal CD and stricturing/penetrating behavior independently of NOD2/CARD15 status, and may prove useful in risk‐stratifying patients to more aggressive antiinflammatory therapies.
Serologic Testing with ANCA, ASCA, and Anti-OmpC in Children and Young Adults with Crohn's Disease and Ulcerative Colitis: Diagnostic Value and Correlation with Disease Phenotype
The ASCA antibodies, while highly specific for CD, identify predominantly the subset of children with disease of the ileum and ascending colon who may be at increased risk of surgery.
Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study.
Prevalence of EIM in Hungarian IBD patients is in concordance with data from Western countries, and supports a role for complex follow-up in these patients.
Disease Location, Anti-Saccharomyces cerevisiae Antibody, and NOD2/CARD15 Genotype Influence the Progression of Disease Behavior in Crohn’s Disease
The progression of disease type in Crohn’s disease is associated with the need for more frequent surgery and consideration should be given to a separate Vienna classification for perianal disease.
Sero-Reactivity to Microbial Components in Crohn's Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype
Reactivity to microbial components is associated with severe CD characterized by small bowel involvement, frequent disease progression, longer disease duration, and greater need for intestinal surgery.
Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.
A large range in sensitivities and specificities of ASCA for CD is seen with different ASCA assays, mainly as a consequence of the cutoff value chosen for each individual assay.